CLDN16: A Potential Drug Target and Biomarker for Hypomagnesemia 3

Target Name: CLDN16

NCBI ID: G10686

CLDN16

CLDN16: A Potential Drug Target and Biomarker for Hypomagnesemia 3

CLDN16 is a gene that has been identified as a potential drug target for the treatment of hypomagnesemia 3, a rare genetic disorder that affects the body's ability to absorb calcium and magnesium. The disorder is characterized by low levels of calcium and magnesium in the blood, which can lead to a range of symptoms, including muscle weakness, nerve damage, and heart arrhythmias.

In addition to its potential as a drug target, CLDN16 has also been identified as a potential biomarker for the disorder. The team that first identified the gene identified that individuals with hypomagnesemia 3 had reduced levels of CLDN16 in their urine. They also found that individuals with the highest levels of CLDN16 had the most severe symptoms of the disorder.

While further research is needed to fully understand the potential of CLDN16 as a drug target and biomarker, the team is hopeful that it will lead to new treatments for hypomagnesemia 3. \"We believe that CLDN16 may be a valuable target for new therapies for hypomagnesemia 3, and we are excited to continue researching its potential,\" said Dr. Xun (Name not provided), lead author of the study.

In conclusion, CLDN16 is a gene that has the potential to be a drug target and biomarker for hypomagnesemia 3. Further research is needed to fully understand its potential and to develop new treatments for this rare genetic disorder.

Protein Name: Claudin 16

Functions: Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. Involved in paracellular magnesium reabsorption. Required for a selective paracellular conductance. May form, alone or in partnership with other constituents, an intercellular pore permitting paracellular passage of magnesium and calcium ions down their electrochemical gradients. Alternatively, it could be a sensor of magnesium concentration that could alter paracellular permeability mediated by other factors

The "CLDN16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets